V2 Financial group LLC Acquires New Position in Becton, Dickinson and Company (NYSE:BDX)

V2 Financial group LLC bought a new position in Becton, Dickinson and Company (NYSE:BDX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,540 shares of the medical instruments supplier’s stock, valued at approximately $349,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. CWM LLC boosted its stake in shares of Becton, Dickinson and Company by 0.6% in the 3rd quarter. CWM LLC now owns 8,965 shares of the medical instruments supplier’s stock valued at $2,161,000 after purchasing an additional 57 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt lifted its stake in Becton, Dickinson and Company by 429.2% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 2,466 shares of the medical instruments supplier’s stock worth $594,000 after purchasing an additional 2,000 shares during the last quarter. First Affirmative Financial Network boosted its position in Becton, Dickinson and Company by 11.9% during the third quarter. First Affirmative Financial Network now owns 1,226 shares of the medical instruments supplier’s stock valued at $296,000 after buying an additional 130 shares during the period. Matrix Asset Advisors Inc. NY grew its stake in shares of Becton, Dickinson and Company by 37.6% during the third quarter. Matrix Asset Advisors Inc. NY now owns 35,295 shares of the medical instruments supplier’s stock valued at $8,510,000 after buying an additional 9,645 shares during the last quarter. Finally, Cardinal Capital Management Inc. purchased a new position in shares of Becton, Dickinson and Company in the third quarter worth about $30,089,000. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $230.22 on Monday. The business has a 50 day moving average of $232.07 and a 200 day moving average of $234.04. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $251.99. The company has a market cap of $66.77 billion, a PE ratio of 38.24, a P/E/G ratio of 1.65 and a beta of 0.40. The company has a quick ratio of 0.74, a current ratio of 1.13 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 14.41 earnings per share for the current year.

Becton, Dickinson and Company declared that its board has initiated a stock buyback plan on Tuesday, January 28th that allows the company to buyback 10,000,000 shares. This buyback authorization allows the medical instruments supplier to purchase shares of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.81%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 69.10%.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 638 shares of the company’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $219.03, for a total value of $139,741.14. Following the sale, the executive vice president now directly owns 14,217 shares of the company’s stock, valued at $3,113,949.51. This represents a 4.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP David Shan sold 500 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the transaction, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at $1,377,840. This represents a 8.01 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 9,844 shares of company stock valued at $2,210,716. Corporate insiders own 0.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on BDX shares. StockNews.com lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Piper Sandler raised their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $283.00.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.